Exploring the biology of vascular calcification in chronic kidney disease: What's circulating?

Kidney International

Volumn 73, Issue 4, 2008, Pages 384-390

  Schoppet, M ^a   Shroff, R C ^b   Hofbauer, L C ^c   Shanahan, C M ^a,d  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Calcification inhibitors; Chronic kidney disease; Matrix vesicles; Vascular calcification; Vascular smooth muscle cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CALCIUM; CALCIUM PHOSPHATE; FETUIN A; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MATRIX GLA PROTEIN; NUCLEOTIDE PYROPHOSPHATASE; OSTEOPROTEGERIN; PHOSPHATE; PHOSPHODIESTERASE I; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARTILAGE CELL; CELL DAMAGE; CELL DEATH; CELL DIFFERENTIATION; CELL TRANSFORMATION; CELL VACUOLE; CHRONIC KIDNEY DISEASE; CIRCULATION; HEART VALVE; HUMAN; HYPERPHOSPHATEMIA; NONHUMAN; PHENOTYPE; PREMATURE AGING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SOFT TISSUE CALCIFICATION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

EID: 38749126786     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002696     Document Type: Article

References (37)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119.
2. Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 2006; 260: 231-237.
3. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
4. Shanahan CM. Mechanisms of vascular calcification in renal disease. Clin Nephrol 2005; 63: 146-157.
5. Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005; 45: 494-501.
6. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867.
7. Schafer C, Heiss A, Schwarz A et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366.
8. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
9. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-1057.
10. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
11. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568.
12. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol 2005; 25: 686-691.
13. Galvin KM, Donovan MJ, Lynch CA et al. A role for Smad6 in the development and homeostasis of the cardiovascular system. Nat Genet 2000; 24: 171-174.
14. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003; 278: 22144-22152.
15. Reynolds JL, Skepper JN, McNair R et al. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920-2930.
16. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross sectional study. Lancet 2003; 361: 827-833.
17. Osawa M, Tian W, Horiuchi H et al. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet 2005; 116: 146-151.
18. Stenvinkel P, Wang K, Qureshi AR et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392.
19. Soriano S, Gonzalez L, Martin-Malo A et al. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clin Nephrol 2007; 67: 352-357.
20. Schurgers LJ, Teunissen KJ, Knapen MH et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25: 1629-1633.
21. Munroe PB, Olgunturk RO, Fryns JP et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 1999; 21: 142-144.
22. Brancaccio D, Biondi ML, Gallieni M et al. Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005; 25: 548-552.
23. Avbersek-Luznik I, Balon BP, Rus I, Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 2005; 20: 566-570.
24. Rhee EJ, Oh KW, Lee WY et al. The differential effects of age on the association of KLOTHO gene polymorphisms with coronary artery disease. Metabolism 2006; 55: 1344-1351.
25. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 2007; 18: 2600-2608.
26. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2495-2500.
27. Nitta K, Ishizuka T, Horita S et al. Soluble osteopontin and vascular calcification in hemodialysis patients. Nephron 2001; 89: 455-458.
28. Brenner D, Labreuche J, Touboul PJ et al. Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients. Stroke 2006; 377: 1691-1696.
29. Pennisi P, Signorelli SS, Riccobene S et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 2004; 15: 389-395.
30. Iba K, Takada J, Yamashita T. The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients. J Bone Miner Metab 2004; 22: 594-596.
31. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32: 388-394.
32. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43.
33. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165: 625-630.
34. Jono S, Ikari Y, Vermeer C et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004; 91: 790-794.
35. O'Donnell CJ, Shea MK, Price PA et al. Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification. Arterioscler Thromb Vasc Biol 2006; 26: 2769-2774.
36. Lomashvili KA, Cobbs S, Hennigar RA et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392-1401.
37. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114.